An intestinal bowel disease that affects up to 10 percent of premature infants at a very vulnerable and developmentally crucial time can lead to serious infection and death. Scientists at the Wake ...

Israeli biotech firm Pluristem Therapeutics said it hopes its anti-radiation therapy will protect Fukushima workers decommissioning nuclear reactors and save lives in the future if ever a similar ...

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc., a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced it will present ...

FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial ...

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (“Celularity”), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies derived from post ...

New firm will start with $11M funding from Japanese investors Sosei Corporate Venture Capital (Sosei CVC) and Pluristem are establishing a Japanese company that will carry out clinical development and ...

A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency, as reported in the peer-reviewed journal Human Gene ...

In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective ...

New Rochelle, NY, December 15, 2020--A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency, as reported in the ...

We examined the feasibility of gene transfer to rabbit placenta using adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine (PEI) complexes. Pregnant New Zealand White rabbits (n = 17) were ...

Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024 FLORHAM PARK, N.J., ...